The use of autologous ascites-derived exosomes (Aex) has been explored in a phase I colorectal cancer clinical trial whereby 40 advanced stage patients were vaccinated subcutaneously once a week for a total of four weeks with Aex alone or in combination with recombinant GM-CSF [59]. Here, CSF2 is linked to colorectal cancer.